Evangelos Fousteris has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • “I Was Blamed for My Condition—Now I Am Blamed for Its Treatment”: The Migration of Obesity Stigma

    by Theocharis Koufakis, Dimitrios Patoulias, Caterina Conte, Evangelos Fousteris

    Obesity stigma remains a pervasive yet insufficiently recognized social and clinical problem that can compromise healthcare engagement and health outcomes. Over the past decade, substantial efforts have promoted person‐first language, respectful representation, and recognition of obesity as a chronic, biologically regulated disease. However, the advent of highly effective obesity pharmacotherapy has made treatment an increasingly prominent target of obesity stigma: People are now blamed not only for having obesity but also for treating it. Although the immediate focus of judgment has evolved, the underlying willpower‐based model persists: Weight loss is often considered legitimate only when achieved through unaided personal effort. Emerging evidence indicates that users of obesity medications may be evaluated less favorably than individuals losing weight through lifestyle intervention, while metabolic–bariatric surgery has long been associated with the “easy way out” narrative. Treatment‐related stigma may also be present among people living with obesity. It could discourage treatment‐seeking and disclosure, influence clinical decision‐making, undermine long‐term treatment persistence, and reinforce therapeutic inertia and inequalities in care. Addressing treatment stigma does not require indiscriminate medicalization but rather individualized, evidence‐based treatment free from moral judgment. Obesity destigmatization must therefore extend beyond recognition of the disease to acceptance of its treatment.

  • Open Access

    12-month weight-loss trajectories and predictors of response to tirzepatide under individualized dosing: A multicenter real-world study

    by Nikolaos Angelopoulos, Evangelos Fousteris, Dimitra Zianni, Ioannis Androulakis, Rodis Paparodis, Dimos Florakis, Andreas Rizoulis, Ilias Perogamvros, Ploutarchos Tzoulis, Dimitrios Askitis, et al.

  • Early changes in body composition with tirzepatide in adults with obesity: a real-world BIA study

    by Nikolaos Angelopoulos, Andreas Rizoulis, Anastasios Boniakos, Evangelos Fousteris, Voula Mentzelopoulou, Dimitra Zianni, Sarantis Livadas, Rodis Paparodis


  • Open Access

    Obesity in Type 1 Diabetes: Moving Beyond the “Lean” Disease Paradigm to Understand Risk, Complications, and Treatment

    by Anastasios Tentolouris, Theocharis Koufakis, Evangelos Fousteris

    Purpose of Review: Overweight and obesity are increasingly common in people with type 1 diabetes mellitus (T1DM). This narrative review synthesizes current evidence on the epidemiology and mechanisms linking excess adiposity with T1DM, the obesity-associated burden of complications, and approaches to obesity management in this population. Recent Findings: Excess adiposity is now frequent in people with T1DM, approaching general-population prevalence, and obesity may also increase the risk of incident T1DM. In T1DM, weight gain reflects intersecting drivers, including intensive insulin therapy, hypoglycemia-related compensatory intake and activity avoidance, obesity-related insulin resistance, and overlapping genetic/hormonal determinants. Across multiple cohorts, higher adiposity is associated with poorer glycemic control and increased risk of cardiovascular events and mortality, as well as higher risks of retinopathy, diabetic kidney disease, and neuropathy. Evidence to guide treatment in T1DM remains limited. Lifestyle approaches require individualization to minimize hypoglycemia and ketosis. RCTs of adjunct liraglutide demonstrate weight loss and insulin-sparing effects but signal dose-dependent risks of hypoglycemia and ketosis. Early RCTs with semaglutide and tirzepatide suggest substantial weight loss and improved glycemic metrics in selected settings, with vigilance for ketosis. Sodium-glucose cotransporter-2 inhibitors have shown modest HbA1c reductions with small but clinically meaningful weight loss in T1DM; however, they are associated with an increased risk of diabetic ketoacidosis. Bariatric surgery yields large weight loss but only modest glycemic benefit and carries risk of metabolic instability. Summary: Obesity is a common, clinically important comorbidity in T1DM, linked to poorer glycemic outcomes and complications. Longer-term, T1DM-specific RCTs are needed to guide weight management and define the benefit-risk of emerging therapies.


  • Elevated body mass index amplifies inflammation-linked diastolic dysfunction independent of diabetes: a two-year prospective study

    by Evangelos Fousteris, Konstantinos Arvanitakis, Theocharis Koufakis, Anastasios Theodosis-Georgilas, Spiridon Matsagos, Nikolaos Patsourakos, Andreas Melidonis

  • Open Access

    Circulating Beta-Defensin 2 Levels Correlate with Conventional Inflammatory Markers in Infection-Free Individuals with Overweight and Obesity: An Exploratory Study

    by Theocharis Koufakis, Dimitrios Kouroupis, Georgios Dimakopoulos, Theofylaktos Georgiadis, Areti Kourti, Paraskevi Karalazou, Katerina Thisiadou, Panagiotis Doukelis, Ioanna Zografou, Dimitrios Patoulias, et al.

    Background/Objectives: The role of intestinal dysbiosis as an important driver of inflammation in metabolic disorders is becoming increasingly evident. Beta-defensin 2 is an antimicrobial peptide that contributes to innate immunity, while recently it has been suggested as a novel biomarker of gut dysbiosis. However, its role in obesity remains unexplored. This study aimed to compare circulating beta-defensin 2 levels between individuals with overweight and obesity and lean controls. An additional objective was to explore potential correlations between beta-defensin 2 and other inflammatory markers in this population. Methods: The study population consisted of 81 participants (61.7% females) divided into obesity (n = 27), overweight (n = 34), and normal body mass index (n = 20) groups. All participants were free of infection and diabetes mellitus. Beta-defensin 2, interleukin-6, presepsin, high-sensitivity C-reactive protein (hs-CRP), and ferritin were evaluated in the study groups. Results: We did not find significant differences in beta-defensin 2 levels between the groups (p = 0.936). In contrast, hs-CRP levels were higher in people with obesity compared to the sum of participants in the overweight and control groups (p = 0.044), after adjusting for the effects of age, sex, smoking, and vitamin D status. Furthermore, a positive correlation was established between beta-defensin 2 and presepsin values (p = 0.012). Conclusions: The results of the present study demonstrate that obesity is characterized by an aggravation of inflammation, as expressed by elevated hs-CRP levels. Although the study design cannot prove causal relationships, our findings also suggest that beta-defensin 2 levels correlate with the magnitude of systemic inflammation in infection-free individuals living with obesity. The value of the combined evaluation of different biomarkers in obesity-related outcomes warrants further investigation by larger studies.


  • Open Access

    Predictors of left ventricular diastolic dysfunction in type 2 diabetes patients: A 4-year prospective study

    by Evangelos Fousteris, Athanasia Papazafiropoulou, Christos Tountas, Angeliki Angelidi, Spiridon Matsagos, Anastasios Theodosis-Georgilas, Stilianos Chantanis, Stefanos Fousas, Andreas Melidonis


  • The Impact of Continuous Subcutaneous Insulin Infusion Therapy on Efficacy and Safety in a Cohort of Type 1 Diabetes Patients: A 3-Year Prospective Study

    by Andreas Melidonis, Alexandros Kamaratos, Angeliki Angelidi, Petros Thomakos, Spiridon Vrakas, John Bakalis, Evangelos Fousteris, Stella Iraklianou

    Background: Several studies have found improved glycemic control with continuous subcutaneous insulin infusion compared with multiple daily insulin injections for patients with type 1 diabetes, albeit for a relatively short-period of follow-up. This prospective study presents for the first time the optimization of glycemic control with insulin pumps in a cohort of Greek patients with type 1 diabetes for a 3-year follow-up period during the socioeconomic crisis in Greece. Materials and Methods: Ninety-four patients, previously on intensified basal–bolus insulin therapy with poor glycemic control, were initially recruited. Glycosylated hemoglobin (HbA1c), hypoglycemic and diabetic ketoacidosis episodes, pump-related side effects, lipidemic profile, 24-h urine albumin excretion, body mass index, blood pressure, and total daily insulin requirements (bolus and basal) were recorded during the 3-year follow-up. Statistical analysis was initially conducted for the entire study population and after body mass index and gender stratification. Results: Seventy-nine patients completed the study. A statistically significant decrease of HbA1c level ( P < 0.0001) was observed at the end of Year 1 and was retained for the following years for the whole population. Similarly, significantly fewer hypoglycemic episodes occurred during the follow-up period ( P < 0.0001) compared with study entry. Insulin pump treatment was not accompanied with weight changes across all body mass index strata. Conclusions: Continuous subcutaneous insulin infusion achieved almost optimal glycemic control, reduced the number of hypoglycemic episodes without weight gain, and was well tolerated for the whole study period. Finally, this therapeutic approach was accompanied with lower daily insulin requirements.


  • Head-to-head comparison of 2 inflammatory biomarkers for the long-term prediction of left ventricular diastolic dysfunction in type 2 diabetes patients: Soluble ST2 versus hs-CRP

    by Evangelos Fousteris, Anastasios Theodosis-Georgilas, Stelios Chantanis, Panayota Spiropoulou, Sophie Mavrogeni, Theofanis Economopoulos, Eleni Boutati, George Dimitriadis, Stefanos Foussas, Andreas Melidonis


  • Open Access

    Evaluation of IScore validity in a Greek cohort of patients with type 2 diabetes

    by Vasileios Dragoumanos, Konstantinos N Tzirogiannis, Georgios I Panoutsopoulos, Konstantinos Krikonis, Evangelos Fousteris, Maria Vourvou, Georgios Elesnitsalis, Nikolaos Melas, Kalliopi T Kourentzi, Andreas Melidonis

    Background: Diabetes constitutes a risk factor for stroke that also aggravates stroke prognosis. Several prognostic models have been developed for the evaluation of neurologic status, severity, short-term functional outcome and mortality of stroke patients. IScore is a novel tool recently developed in order to predict mortality rates within 30 days and 1 year after ischemic stroke and diabetes is not included in the scoring scale of IScore. The aim of the present study was to evaluate and compare IScore validity in ischemic stroke patients with and without diabetes. Methods: This prospective study included 312 consecutive Caucasian patients with type 2 diabetes and 222 Caucasian patients without diabetes admitted for ischemic stroke in a tertiary Greek hospital. Thirty-day and 1-year IScores were individually calculated for each patient and actual mortality was monitored at the same time intervals. IScore’s predictive ability and calibration was evaluated and compared for ischemic stroke patients with and without diabetes. The performance of IScore for predicting 30 and 1-year mortality between patients with and without diabetes was assessed by determining the calibration and discrimination of the score. The area under the receiver operating characteristic curve was used to evaluate the discriminative ability of IScore for patients with and without diabetes, whereas the calibration of IScore was assessed by the Hosmer–Lemeshow goodness-of fit statistic. Results: Baseline population characteristics and mortality rates did not differ significantly for both cohorts. IScore values were significantly higher for patients with diabetes at 30 days and 1 year after ischemic stroke and patients with diabetes presented more frequently with lacunar strokes. Based on ROC curves analysis IScore’s predictive ability for 30 day mortality was excellent, without statistically significant difference, for both cohorts. Predictive ability for 1 year mortality was also excellent for both groups with significantly better ability for patients with diabetes especially at high score values. Calibration of the model was good for both groups of patients. Conclusions: IScore accurately predicts mortality in acute ischemic stroke Caucasian patients with and without diabetes with higher efficacy in predicting 1 year mortality in patients with diabetes especially with high scores.